J&J Claims Guidant For $23.9 Bil., Forms CV Device Group Under Valeriani

Johnson & Johnson's willingness to pay $24 bil. (6.5-times revenue) for Guidant validates the long-standing claim of ICD manufacturers that the cardiac rhythm management market is largely underserved